Drug
Finotonlimab clinical trials
Also written SCT-I10A.
- studies test it
- 7
- open now
- 3
- in phase 3
- 2
- first study started
- 2018
Keep track of what changes. Save the finotonlimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Combined with it in one product
Studies by the year they started
7 studies that test it; most in 2026 (2)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
- Phase 2
- 3
- Phase 3
- 2
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 3
Sinocelltech Ltd. (4) · Sun Yat-sen University (1) · Tang-Du Hospital (1) · Beijing Tongren Hospital (1)
Often tested with
Tested in the same studies.
Docetaxel (2) · Paclitaxel (2) · SCT510 (1) · Cetuximab (1) · Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Stapokibart (1)
Studies
Open first, then newest update. How each study uses finotonlimab is read from its arms, and is right about nine times in ten.
Testing it · 7
- Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal CarcinomaNot yet recruitingPhase 2Tang-Du HospitalNCT07752394Written as Finotonlimab
- BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy ProgressionEnrolling by invitationPhase 2Sun Yat-sen UniversityNCT07618624Written as Finotonlimab
- Finotonlimab Combined With Stapokibart in the Treatment of Recurrent/Metastatic HNSCCRecruitingPhase 1Beijing Tongren HospitalNCT07040072Written as Stapokibart and Finotonlimab
- SCT-I10A Plus SCT510 Versus Sorafenib as First-Line Therapy for Advanced Hepatocellular CarcinomaActive, not recruitingPhase 2/3Sinocelltech Ltd.NCT04560894Written as SCT-I10A
- SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell CarcinomaStatus unknownPhase 1Sinocelltech Ltd.NCT05552807Written as SCT-I10A
- SCT-I10A Plus Standard Chemotherapy in First-line Recurrent/ Metastatic Head and Neck Squamous Cell CarcinomaStatus unknownPhase 3Sinocelltech Ltd.NCT04146402Written as SCT-I10A+chemo
- Safety, Tolerability, Pharmacokinetics and Efficacy of SCT-I10A in Patients With Advanced Solid Tumors or LymphomaStatus unknownPhase 1Sinocelltech Ltd.NCT03821363Written as SCT-I10A
Given in every arm · 2 — finotonlimab is usual care beside what is tested
- A Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular CarcinomaRecruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT06986785Written as Finotonlimab
- Study of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in ESCC and CRCStatus unknownPhase 1Sinocelltech Ltd.NCT04229537Written as SCT-I10A
Codes
What other systems call finotonlimab · ClinicalTrials.gg INT014982
- UNII (FDA) 533Z4G2286FINOTONLIMABOne source FDA
- NCI Thesaurus C170758FinotonlimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 533Z4G2286 | FINOTONLIMAB | One source FDA |
| NCI Thesaurus | C170758 | Finotonlimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.